Astellas Venture Management

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma, one of the world's leading pharmaceutical companies. Founded in 2005 and headquartered in South San Francisco, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies for over twenty years. The investment thesis is explicitly strategic: AVM targets science that enhances the Astellas R&D pipeline or catalyzes new directions in discovery research, with the team's Pharma View serving as both a selection lens and a support framework. AVM has invested in 61 companies across 104 total investment rounds, deploying $3 million to $20 million per company at seed through Series B stages. Series A is the most active stage, with 19 investments averaging $33.8 million in round size. Notable current portfolio companies include Solu Therapeutics, Syntax Bio, PhoreMost, and Somite. The most recent investment was in Solu Therapeutics in April 2025, and the most recent exit was Orna Therapeutics in February 2026. A team of eight, including three partners and one principal, spans the US and Japan. AVM's principal value to portfolio companies is its deep pharmaceutical industry expertise and the pathway it opens to Astellas Pharma: strategic licensing dialogues, research collaborations, and potential acquisitions that purely financial investors cannot facilitate. For early-stage biotech founders, AVM's Pharma View means receiving guidance from investors who understand drug development not as outsiders but as participants in the global pharmaceutical system.